University of Calfornia San Diego
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Graves, Jennifer S
NEOS, NCT04926818 / 2020-002700-39: Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

Active, not recruiting
3
129
Europe, Canada, US, RoW
Fingolimod, FTY720, Ofatumumab, OMB157, Siponimod, BAF312, Fingolimod placebo, Siponimod placebo, Ofatumumab placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Multiple Sclerosis (MS)
03/27
11/31
NCT03958877 / 2018-003008-38: A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Active, not recruiting
3
142
Europe, US, RoW
BIIB017 (peginterferon beta-1a), PLEGRIDY, Interferon beta type 1a, Avonex
Biogen
Multiple Sclerosis, Relapsing-Remitting
05/27
05/27
NCT05549258 / 2021-003528-33: Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

Recruiting
2
15
Europe, Canada, US, RoW
Inebilizumab
Amgen, Horizon Therapeutics Ireland DAC
Neuromyelitis Optica Spectrum Disorder
04/27
04/27
NCT04746976: Study of Diroximel Fumarate in the Real-World Setting

Terminated
N/A
75
US
Diroximel Fumarate, VUMERITY, BIIB098
Biogen
Relapsing Forms of MS
04/23
04/23
Miner, Annalise
NCT04746976: Study of Diroximel Fumarate in the Real-World Setting

Terminated
N/A
75
US
Diroximel Fumarate, VUMERITY, BIIB098
Biogen
Relapsing Forms of MS
04/23
04/23

Download Options